skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Strategic industry insight

Contact us to get more information

Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential  deals, R&D, commercial and market access strategies. 

How it helps 

With In Vivo, you’ll benefit from:

  • Insight about the key players in the industry
  • In-depth coverage of company strategies
  • Expert analysis of deal making, R&D, commercial, market access and finance strategies and trends
  • Exclusive insider insight and thought leadership
  • Help with specific questions from our renowned Ask-the-Analyst™ service



How it works

Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service. 

Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.

What's included

Pharma Intelligence: latest

  • In Vivo

    Five (Non-COVID) Clinical Trial Hits Of 2021

    By Alex Shimmings 05 Jan 2022

    IV012022_hittarget

    2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.

  • In Vivo

    Innovation Trends Point To More Positives For Health Care Investors

    By Ashley Yeo 28 Dec 2021

    COVIDgears

    At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.

  • In Vivo

    A New Generation Invents Pharma’s Mirrored Future

    By Joanne Shorthouse 17 Nov 2021

    IV122021_DigitalTwinAI_KXFFFB_1200

    Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.

  • In Vivo

    ‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

    By William Masters 16 Aug 2021

    IV0821_HIV2_2EA9AFG

    Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

  • In Vivo

    Biotechs Choosing Brazil For Drug Development And Early Sales

    By Mark Ratner 12 Aug 2021

    IV082021_RareDiseaseBrazil

    Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

  • In Vivo, Pink Sheet

    Manufacturing and Distribution: Challenges and Opportunities

    13 May 2021

    Manufacturing and Distribution eBook

    The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

    Topic Strategy

  • In Vivo

    Pandemic Puts A Spotlight On Counterfeit Drugs

    By William Masters 13 Apr 2021

    IV0421_Drug_Question_Mark_M4AH5C_1200

    As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

  • In Vivo

    At War With A Pandemic: Manufacturing For Our Lives

    By Joanne Shorthouse 10 Mar 2021

    IV2103_MF_Corona_1676169577_1200

    The rapid development of a vaccine to fight COVID-19 is an effort that will be discussed and admired for centuries to come. The effort to make and deliver the vaccines to those who are most at risk is a battle all of its own. Two manufacturers talk to In Vivo about managing roll out strategies when the whole world is watching.

  • In Vivo

    Pandemic Perspectives: Pharma Must Not Let Its COVID-19 Halo Slip

    By Daniel Chancellor 03 Mar 2021

    IV2103_PP_Halo_1675458667

    Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.

  • In Vivo

    The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

    27 Jan 2021

    The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

    The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.

    Topic Regulation Market Access Medtech-Brexit

  • In Vivo

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    By William Looney 27 Nov 2020

    ESG_In_2020_1

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

    Topic Financing Strategy

  • In Vivo

    Curing What Hinders Alzheimer’s Drug Development

    By Rachel Laing, Alessia Deglincerti, Mark Ratner 27 Nov 2020

    Curing What Hinders Alzheimer’s Drug Development

    Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

    Topic Alzheimer's Disease Drug Development Landscape

  • In Vivo

    A Tale Of Two Pipelines

    By Dennis Chang; Keith Flaherty; Uciane Scarlett 27 Nov 2020

    A_Tale_Of_Two_Pipelines_1

    Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

    Topic Cancer Research & Development

  • In Vivo, Medtech Insight

    Transforming Cancer Treatment with Early Detection Diagnostics: Opportunities And Obstacles Webinar

    27 Oct 2020

    Early Diagnostic webinar slides

    Join distinguished cancer and industry experts as they explore what a shift in cancer treatment – from late stage intervention to an early detection paradigm – would mean for patient outcomes, cancer costs, technology, development, regulatory affairs, and more. Explore this new approach toward focusing on early stage cancer detection, including discussion of diagnostics in this area, such as biomarker identification, liquid biopsies, and monitoring technologies.

    Topic Diagnostics Cancer

  • In Vivo

    Success in Oncology Infographic

    24 Aug 2020

    Success in Oncology Infographic

    As events and developments in oncology rapidly shift and unfold, it’s more critical than ever to stay vigilant and agile to stay ahead.Understand these market disruptions and react to them with confidence with the data in Innovation in Oncology, the vital, free infographic from In Vivo.

    Topic Cancer

Meet the team

Editor

William Looney

Editor, Executive Editor, In Vivo
William Looney

William specializes in

  • Biopharma Pipeline Strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy & Regulation

42+ years of experience

Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC

Denise Peterson

Denise specializes in

  • Commercial Strategy
  • Policy & Regulation

40+ years of experience

Editor

Ian Schofield

Editor, Executive Editor, Pharma Insights
Ian Schofield

Ian specializes in

  • Policy & Regulation
  • Biosimilars
  • Generics
  • Market Access
  • Pricing & Reimbursement

37+ years of experience

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: